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Abstract
Objectives: Patients undergoing complex hepatopancreatobiliary (HPB) operations are at high risk for
surgical site infection (SSI). Factors such as biliary obstruction, operative time and pancreatic or biliary
fistulae contribute to the high SSI rate. The purpose of this study was to analyse whether a multifactorial
approach would reduce the incidence and cost of SSI after HPB surgery.
Methods: From January 2007 to December 2009, 895 complex HPB operations were monitored for SSI
through the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP).
In 2008, surgeon-specific SSI rates were provided to HPB surgeons, and guidelines for the management
of perioperative factors were established. Observed SSI rates were monitored before and after these
interventions. Hospital cost data were analysed and cost savings were calculated.
Results: Observed SSI for hepatic, pancreatic and complex biliary operations decreased by 9.6% over
a 2-year period (P < 0.03). The excess cost per SSI was US$11 462 and was driven by increased length
of stay and hospital readmission for infection. Surgeons rated surgeon-specific feedback on SSI rate as
the most important factor in improvement.
Conclusions: High SSI rates following complex HPB operations can be improved by a multifactorial
approach that features process improvements, individual surgeon feedback and reduced variation in
patient management.
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Introduction
Despite improvements in mortality following hepatic, pancreatic
and complex biliary surgery, rates of overall morbidity and surgi-
cal site infection (SSI) subsequent to these procedures remain
high.1 Reducing postoperative infection is important following
hepatopancreatobiliary (HPB) operations because mortality has
been associated with such complications.2–5 Historically, the rate
of SSIs occurring within 30 days of HPB surgery has been high,
reaching 20–40%.6–8 However, very few reports have addressed
methods to reduce SSIs in these patients.
The factors that contribute to the occurrence of SSIs after HPB
surgery are numerous and are more clearly subdivided into preop-
erative, intraoperative and postoperative categories. Preoperative
factors include patient comorbid conditions (obesity, cardiopul-
monary disease, bleeding disorder), malnutrition (weight loss,
anorexia) and HPB pathology (bactibilia, biliary obstruction,
malignancy).1,9,10 Intraoperative factors include long operative
times,11,12 significant blood loss related to the division of major
vascular structures,12,13 and complex biliary/pancreatic–enteric
anastomoses.10 Postoperative factors include the development of
pancreatic and biliary fistulae.14,15 The aims of this study were to
determine whether a multifactorial approach to address known
risk factors would decrease the incidence of SSI in HPB surgical
patients and, if so, to document the cost savings.
Materials and methods
American College of Surgeons National Surgical
Quality Improvement Program
The American College of Surgeons National Surgical Quality
Improvement Program (ACS-NSQIP) is a national, validated,
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outcomes-based, risk-adjusted, peer-controlled programme for
the measurement and enhancement of the quality of surgical care.
The sampling strategy, data abstraction procedures, variables col-
lected and structure have been published.16–19 A total of 136 preop-
erative (patient characteristics), intraoperative (processes of care)
and postoperative (adverse outcomes) variables were prospec-
tively collected by a trained, certified nurse reviewer (EMK). Sur-
gical clinical nurse reviewers also ensure the validity of their data
by assessing physician documentation and by contacting patients
directly. Outcomes are assessed at 30 days after the index opera-
tion, and highly standardized and validated definitions are
employed. During the study period, ACS-NSQIP used a system-
atic random sampling process that employed an 8-day cycle,
whereby the first 40 cases to fulfil the inclusion and exclusion
criteria were evaluated. This process therefore excluded an over-
sampling of minor cases. Patients aged < 16 years were excluded.
Quality was ensured by inter-rater reliability audits, as well as by
online decision support, so that the level of disagreement within
ACS-NSQIP was only 1.53% for all variables during the study
period.
Patient population
The ACS-NSQIP database at Indiana University Hospital was
queried to identify all patients who had undergone hepatic, pan-
creatic or complex biliary surgical procedures between 1 January
2007 and 31 December 2009. The current procedural codes for
these operations can be found in the Appendix. These codes were
used to identify all patients for analysis with complete 30-day
outcomes for all variables. During the study period, more than
90% of HPB operations performed at Indiana University Hospital
were captured in the ACS-NSQIP database. Institutional review
board approval for the analysis of patients undergoing HPB
surgery was obtained prior to initiation of this analysis.
Risk factors
During the first year of this analysis (2007), SSI rates were deter-
mined for hepatic, pancreatic and complex biliary surgery. In 2007
efforts to improve intraoperative glucose and temperature
control, and to limit intraoperative blood transfusions were initi-
ated. Once the observed SSI rates were reported in 2008, surgeon-
specific rates were determined for hepatic, pancreatic and
complex biliary operations, respectively, and fed back to the indi-
vidual surgeons. Specific factors thought to be associated with
high risk for the development of SSI were also identified (Table 1).
These preoperative, intraoperative and postoperative factors were
discussed by the HPB surgeons in 2008 when the 2007 data were
available. Considerable consensus was reached with respect to
preoperative nutrition, perioperative antibiotic management,
blood transfusions, glycaemic control, temperature control, sur-
gical technique and wound protection. Standardization of post-
operative oxygenation, glucose control, and drain and wound
management was also implemented. All of these changes were
intended to streamline care provided to patients undergoing HPB
surgery performed by eight HPB surgeons. Outcomes were then
followed in 2008 and 2009 after the implementation of these
changes. Thus, multiple potential risk factors were addressed
simultaneously.
Outcomes
Outcomes collected by ACS-NSQIP were assessed at 30 days
regardless of whether the patient had been discharged, remained
hospitalized or had been admitted to a different institution. Out-
comes including patient demographics, comorbidities, mortality
(all-cause death within 30 days after the operation) and 30-day
overall morbidity were recorded, but the primary endpoint
assessed in this study was SSI. Surgical site infections were
divided into two groups comprising superficial (superficial or
deep incisional) infection and organ space infection (OSI),
respectively. Superficial SSI was defined as an infection which
occurred within 30 days after the index operative procedure and
involved either skin/subcutaneous tissue (superficial) or the
fascial/muscle layer (deep) of the incision, in a patient with at
least one of the following:
1 purulent drainage from the incision but not from the organ/
space component of the surgical site;
2 organisms isolated from an aseptically obtained culture of fluid
or tissue from the superficial incision;
3 at least one of the signs or symptoms of infection, including
pain or tenderness, localized swelling, redness and heat and a
superficial incision deliberately opened by a surgeon and either
found to be culture-positive or not cultured (a culture-negative
finding did not meet this criterion);
Table 1 Risk factors for surgical site infection in hepatopancreato-
biliary surgery
Preoperative Bactibilia
Biliary obstruction
Diabetes
Malignancy
Nutrition
Obesity
Intraoperative Antibiotic administration
Blood transfusions
Glycaemic control
Surgical technique
Temperature control
Wound protection
Postoperative Drain management
Fistula management
Glycaemic control
Oxygenation
Wound management
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4 a deep incision spontaneously dehisced or deliberately opened
by a surgeon and either found to be culture-positive or not
cultured (a culture-negative finding did not meet this criterion)
and at least one of the signs or symptoms of fever (>38 °C),
localized pain or tenderness, and
5 an abscess or other evidence of infection involving the deep
incision found on direct examination, during reoperation, or by
histopathologic or radiologic examination.
Organ space infection was defined as any infection that
occurred within 30 days after the index operative procedure,
appeared to be related to the operative procedure, involved any
part of the body, excluding the skin incision, fascia or muscle
layers, that had been opened or manipulated during the operative
procedure in a patient with at least one of the following:
1 purulent drainage from a drain that was placed through a stab
wound into the organ or space;
2 organisms isolated from an aseptically obtained culture of fluid
or tissue in the organ or space, and
3 an abscess or other evidence of infection involving the organ or
space found on direct examination, during reoperation, or by
histopathologic or radiologic examination.
The observed SSI rate was defined as the percentage of SSIs
observed in all patients undergoing HPB surgery at Indiana Uni-
versity Hospital during the study time period who were moni-
tored via ACS-NSQIP. The expected SSI rate was defined as the
observed SSI rate recorded by ACS-NSQIP for all participating
centres matched for procedure type during the same period.
Secondary endpoints assessed in this analysis included: (i)
length of stay (LoS); (ii) readmission rate, and (iii) variable direct
cost. Length of stay included the hospital stay related to the index
HPB operation as well as any additional days related to readmis-
sion(s). The 30-day all-cause readmission rate was used for this
analysis. Variable direct costs for the index admission and
readmissions were determined for each patient and then grouped
by hepatic, pancreatic and complex biliary operations and aver-
aged. Length of stay, readmissions and costs were also grouped by
patients with: (i) no SSI; (ii) superficial SSI, and (iii) OSI.
HPB SSI questionnaire
In 2010, when 2009 SSI data became available, HPB attending
surgeons and fellows were asked to rate 12 factors that may have
contributed to the improvements in infection rates. The 12 factors
in the HPB SSI Questionnaire were: (i) preoperative patient nutri-
tion; (ii) intraoperative wound protection; (iii) intraoperative
antibiotics; (iv) intraoperative glucose control; (v) intraoperative
temperature control; (vi) intraoperative surgical technique; (vii)
intraoperative blood loss/transfusion; (viii) postoperative oxy-
genation; (ix) postoperative glucose control; (x) postoperative
drain management; (xi) postoperative wound management, and
(xii) surgeon-specific SSI feedback. Each factor was graded on a
5-point Likert scale on which 1 = strongly disagree and 5 =
strongly agree. Questionnaires were returned by seven HPB
faculty members and two HPB fellows.
Statistical analyses
All statistical analyses were performed using sas Version 8.2 (SAS
Institute, Inc., Cary, NC, USA). The Mann–Whitney U-test was
used to compare means of continuous variables. The chi-squared
test was used for non-parametric data. P-values of < 0.05 were
considered to represent statistical significance for all comparisons.
Results
Surgical site infections
The 2007–2009 ACS-NSQIP dataset yielded 895 HPB procedures
performed at Indiana University Hospital. Data on SSIs were ini-
tially subdivided according to whether they referred to hepatic
(Fig. 1a), pancreatic (Fig. 1b) or complex biliary (Fig. 1c) proce-
dures. Figure 1(a–c) compares the observed SSI rates in the initial
period of the study (2007) and in the periods during (2008) and
after (2009) the feedback of surgeon-specific SSI rates and the
standardization of patient management. In addition, the expected
SSI rates became available in 2008 and 2009 and provide a per-
spective of the trends for SSI in HPB surgery in the collective
ACS-NSQIP database. Feedback and standardization decreased
the incidence of observed SSI from 28.1% to 14.2% in hepatic
operations, from 24.3% to 17.1% in pancreatic operations and
from 24.0% to 11.4% in complex biliary operations. By 2009, the
ratios of observed : expected (O : E ratios) SSI were 0.69, 0.79 and
0.47 for each of the three groups, respectively; thus each SSI rate
was lower than the expected national mean. When the data were
tabulated to examine all HPB operations (Fig. 1d), the SSI rate
decreased from 24.8% to 15.2% to give an O : E ratio of 0.77 in
2009. This decrease in SSI rate of 9.6% from the initial observed
2007 rate to the final observed 2009 rate for hepatic, pancreatic and
complex biliary operations was statistically significant (P < 0.03).
Length of stay, readmissions and cost
Further analysis of the clinical and economic impact of SSIs in
HPB surgery was performed for the entire study period. Groups
were created to compare patients without SSI (80%), and those
with either superficial SSI (10.1%) or OSI (9.9%). Mean LoS was
9 days, 12 days and 16 days after surgery in patients with no SSI,
superficial SSI and OSI, respectively (Fig. 2), suggesting that the
severity of infection prolonged hospital stay. Thirty-day readmis-
sion rates were 11.3%, 21.1% and 54.2% in patients with no SSI,
superficial SSI and OSI, respectively (Fig. 3), which again suggests
that the severity of infection increased the readmission rate fol-
lowing discharge from the index operation.
Review of administrative databases revealed mean variable
direct costs of US$12 255, US$18 142 and US$29 230 for patients
with no SSI, superficial SSI and OSI, respectively (Fig. 4), which
suggests that severe infections resulted in much higher medical
costs. When the mean cost for patients with no SSI was compared
with the mean cost for all SSIs (superficial plus organ space infec-
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Figure 1 Rates of surgical site infection (SSI) in (a) hepatic surgery, (b) pancreatic surgery, (c) complex biliary surgery and (d) composite
hepatic, pancreatic and complex biliary surgery. *P < 0.03 versus 2007 observed SSI rate. Note that expected (national) SSI rates decreased
in 2009 compared with 2008
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Figure 2 Length of stay in days following the operation. Patients
were grouped according to whether they experienced no surgical
site infection (SSI) (80.0%), superficial SSI (10.1%) or organ space
infection (OSI; 9.9%). *P < 0.05 versus no SSI
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Figure 3 Readmission rates at 30 days in all patients. Patients were
grouped according to whether they experienced no surgical site
infection (SSI) (80.0%), superficial SSI (10.1%) or organ space infec-
tion (OSI; 9.9%). *P < 0.05 versus no SSI
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tions), a mean cost difference of US$11 462 per infection was
observed. Compared with 2007, the overall HPB infection rate was
reduced by 9.6%, which translated into 32.3 fewer infections per
year. In 2009 342 HPB operations were performed. At a cost of
US$11 462 extra per infection, the cost savings in 2009 amounted
to US$370 223.
Surgeon ratings of risk factors
The HPB surgeons and fellows thought that surgeon-specific SSI
feedback was the most important factor in reducing the incidence
of SSIs and awarded this factor a mean score of 4.75 (Table 2).
Surgical technique and wound protection were believed to be the
next most important factors; each of these achieved a mean score
of 4.13. Antibiotic management, primarily re-dosing during long
operations, was the fourth most important factor, achieving a
mean score of 3.75. The next five factors obtained mean scores of
3.25 or 3.38, only slightly above a score designating ‘neutral’. Blood
transfusions and wound management were rated as ‘neutral’,
whereas postoperative oxygenation was not thought to play a role
in reducing the occurrence of SSI.
Discussion
Surgical site infection in HPB surgery remains an important
morbidity that requires further attention from surgeons in order
to improve patient outcomes. In the initial year of this study
(2007), SSI rates were 28.1%, 24.3%, 24.0% and 24.9% for
hepatic, pancreatic, complex biliary and all HPB operations,
respectively. These data, provided by participation in ACS-
NSQIP, stimulated the present group to strive for a lower SSI rate
in HPB patients operated at this centre. As a result of surgeon-
specific feedback and clinical management changes, SSI rates sig-
nificantly decreased to 14.2%, 17.1%, 11.4% and 15.1% for
hepatic, pancreatic, complex biliary and all HPB operations,
respectively, in 2009. The clinical impact of SSI was evident in
that patients with an infection had a longer LoS following
surgery and required more readmissions. Approximately one half
of infections were OSIs and these serious infections significantly
(P < 0.05) increased LoS and readmissions. In turn, the economic
impact of SSIs was fiscally relevant in that each SSI imposed an
additional mean direct variable cost of US$11 462 on the health
care system. The cost per SSI was primarily driven by the
increased LoS and readmissions required by the necessity for
more intensive medical therapy, including percutaneous drainage
and reoperations for intra-abdominal abscesses.
Ambiru et al. documented incidences of SSI following HPB
surgeries and reported SSI rates of 26%, 28% and 60% for hepatic,
pancreatic and complex biliary procedures, respectively.10 In a
univariate analysis, they identified significant risk factors for SSI
to include preoperative obstructive jaundice, pancreatobiliary
malignancies, number of enteric anastomoses, blood transfusion
and postoperative glucose control.10 Further multivariate analysis
found that biliary malignancies, three or more enteric anastomo-
ses and poor postoperative glycaemic control were related to SSI.10
Factors such as an underlying malignancy or the number of anas-
tomoses cannot easily be controlled. However, intra- and postop-
erative glucose control are most likely to be very important in
HPB surgery. In the period referred to in the current study, tight
postoperative glucose control was accomplished in 2007, but
intraoperative glucose control was implemented in 2008.
A risk factor for SSI that is pertinent and has not been
adequately studied is the presence of pancreatic or biliary fistu-
lae.14,15 The present group previously reported OSI rates in pan-
creatic surgery for 2006–2009 at all centres participating in
ACS-NSQIP.20 This analysis found that OSI rates following pan-
creatic surgery were 10–11% and had not changed over a 4-year
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Figure 4 Mean direct variable hospital costs (US$1000). Patients
were grouped according to whether they experienced no surgical
site infection (SSI) (80.0%), superficial SSI (10.1%) or organ space
infection (OSI; 9.9%). *P < 0.05 versus no SSI
Table 2 Surgeon questionnaire ratings of factors influencing a
decrease in the incidence of surgical site infection (SSI) in hepato-
pancreatobiliary surgery, scored on a scale of 1–5
Mean score
Surgeon SSI feedback 4.75
Surgical technique 4.13
Wound protection 4.13
Antibiotic management 3.75
Drain management 3.38
Glycaemic control,
postoperative
3.38
Glycaemic control,
intraoperative
3.25
Preoperative nutrition 3.25
Temperature control 3.25
Blood transfusions 3.00
Wound management 3.00
Postoperative oxygenation 2.63
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period. Organ space infections as documented in the ACS-NSQIP
database represent a reasonable surrogate for Grade B and C fis-
tulae as defined by the International Study Group on Pancreatic
Fistula (ISGPS). Currently, efforts are underway at this institution
to define the relationship between OSI and pancreatic fistula.
In addition, a national Pancreatectomy Demonstration Project
within ACS-NSQIP should further clarify this relationship and
has the potential to improve outcomes.
A review of secondary endpoints in this study, including LoS,
readmissions and cost, documented that they were driven prima-
rily by the occurrence of SSIs. Furthermore, these endpoints were
all found to increase progressively. These findings are not novel in
that other surgical disciplines have reported that SSI increases LoS
and readmission rates, and that OSI has a greater impact than
superficial SSI in hip arthroplasty, colorectal, vascular and
common general surgical procedures.21–24 Broex et al. published a
meta-analysis reviewing studies that reported findings focusing
on the absence or presence of SSI affecting LoS and cost.25 They
found that health care-related costs were twice as high in patients
with SSI and that this rise in costs was primarily dependent on an
increased LoS. The findings in the present series are similar in that
the 80.0% of HPB patients in whom SSI did not occur had the
shortest LoS (9 days), the lowest readmission rate (11.0%) and
incurred the lowest cost (US$12 225). The 10.1% of HPB patients
in whom a superficial SSI occurred had an increased LoS (12 days)
and a higher readmission rate (21.1%) and incurred higher costs
(US$18 124). However, the 9.9% of HPB patients affected by an
OSI had the longest LoS (16 days), the highest readmission rate
(53.9%) and incurred the highest costs (US$29 230).
In this study, patients were found to have benefited from the
changes implemented by this centre’s HPB surgeons in terms of a
lower incidence of SSI, as well as a shorter LoS and lower readmis-
sion rate. In addition, the health care system benefited from the
lower medical costs. The calculated saving of >US$370 000 in a
single year (2009) for a relatively small subset of patients is par-
ticularly valuable in the current era of health care cost contain-
ment. This example also confirms the paradigm that increased
quality is associated with reduced cost. An additional subtle
benefit of streamlining clinical management refers to the dis-
course that occurred among the eight HPB surgeons. A better
understanding of each surgeon’s preoperative approach, operative
technique and postoperative management was open for discus-
sion. In retrospect, each surgeon recalled learning about new
aspects of care provided by his or her colleagues that had not
previously been voiced or written. Although the study period
concluded in 2009, nearly all of the clinical guidelines for the
management of HPB operations have been maintained over time.
A recent review of 2011 ACS-NSQIP data for SSI following pan-
createctomy found an odds ratio of 0.84 in 2011, which is similar
to the O : E ratio of 0.77 reported for 2009. Thus, surgeon feed-
back and reductions in variation in clinical management led to
improvements in the rate of SSIs that persisted beyond the study
period.
The changes implemented in this study may constitute a
‘bundle’ with which to reduce SSI in HPB surgery. The critical
factors are listed in Table 2 and can be subcategorized by intra-
and perioperative variables. Intraoperative variables include sur-
gical technique, which primarily focuses on limiting the exposure
of colonized bile and enteric contents to the surgical wound.
Various steps are taken to minimize peritoneal and wound soilage,
such as delaying bile duct division or placing bile duct clamps, as
well as ‘isolating’ the gastrointestinal (GI) anastomosis with sterile
towels. Once all GI anastomoses are complete, surgical gloves are
changed, and contaminated towels and instruments, including
the suction device and cautery, are removed from the sterile field
or replaced. Upon completion of the procedure, the abdomen
is irrigated with warm saline and meticulous haemostasis is
achieved. Wound protection is also a part of surgical technique.
Thus, an idophor-impregnated adhesive is routinely placed on the
surgical field prior to the incision and a wound edge protector is
used as a mechanical barrier to bacteria prior to formal explora-
tion with open incisions. In laparoscopic procedures, a specimen
retrieval bag is used routinely. Following fascial closure for open
procedures, the wound is irrigated with warm saline and haemos-
tasis is checked.
Antibiotic administration follows the Surgical Care Improve-
ment Project (SCIP) guidelines with respect to the timing of anti-
biotics, including re-dosing for longer operations. In terms of
antibiotic selection, first-generation cephalosporins are employed
in ‘clean’ cases such as distal pancreatectomy and enucleation.
However, in patients in whom biliary stents have been placed for
obstructive jaundice, antibiotics with a broader spectrum for
biliary organisms are chosen. Intraoperative normothermia is
achieved primarily with patient warming blankets, but as a part of
this study, the use of warmed i.v. fluids was implemented. Intra-
operative glucose control has two purposes, which include preop-
erative screening for undiagnosed diabetes and intraoperative
infusion of i.v. insulin in appropriate patients. In addition, blood
transfusion practices by individual surgeons and anaesthesiolo-
gists were monitored, and practice patterns were discussed, along
with recommendations to limit perioperative transfusions.
Preoperative nutrition is one of the perioperative variables
included in the HPB SSI package. Improving nutritional status was
initially considered to fall within the remit of surgeons, but all HPB
patients are currently seen by a dietician at 2–3 weeks preopera-
tively and provided with recommendations for liquid protein and
vitamin and mineral supplementation. Postoperative variables
include the annual provision of surgeon-specific SSI feedback,
which is considered by the surgeons as the most important factor
in reducing SSIs. Another area in which variation among surgeons
has been reduced concerns drain management. During the study,
the group began to check drain amylase levels earlier and to
remove drains by postoperative day 3.26 In addition, one surgeon
adopted a policy of no drain use. Postoperative glycaemic control
was fully implemented at this institution prior to the initiation
of this analysis. In addition, postoperative wound management
HPB 389
HPB 2013, 15, 384–391 © 2012 International Hepato-Pancreato-Biliary Association
focused on resident and physician extender education about dis-
tinguishing cellulitis from an SSI and the decision to open a wound
by the attending surgeon. Postoperative oxygenation was also dis-
cussed, but conventional oxygenation was employed as the HPB
surgeons did not believe this variable to be critical.
The limitations of the present study primarily centre on the use
of ACS-NSQIP as the primary method of data acquisition.
Although the vast majority of SSIs in HPB surgery patients occur
within 30 days, the fact that this programme’s data are restricted
to a 30-day postoperative period represents a limitation. The
grouping of all hepatic, pancreatic, complex biliary and all HPB
operations in the assessment of SSI creates heterogeneity in each
group. This grouping has the potential to dilute the SSI rate for the
highest-risk procedures within these particular subgroups. One
additional variable that might skew the data was the volume of
cases performed laparoscopically. Over the study period, no sig-
nificant increase in the number of laparoscopic procedures per-
formed was observed between 2007 and 2009 as the increase in
laparoscopic distal pancreatectomies and enucleations occurred
prior to 2007.27
Perhaps the largest criticism of this analysis is that multiple
processes were changed simultaneously, which makes it difficult
to draw conclusions on cause and effect. The present authors
consider that multiple process improvements were necessary to
improve a disappointingly high SSI rate observed during this
group’s first full year in ACS-NSQIP. In the best interests of
the patient, changes in multiple areas seemed appropriate, and
surgeon-specific feedback on SSI rates also played a key role. In
conclusion, the present authors believe that high SSI rates follow-
ing complex HPB operations can be improved by taking a multi-
factorial approach that features process improvement, the
provision of feedback to individual surgeons, and reduced varia-
tion in patient management.
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Appendix
Procedures in hepatopancreatobiliary surgery by Current Procedural Terminology (CPT) code
Group CPT code Procedure name
Biliary complex 47460 Transduodenal sphincterotomy or sphincteroplasty
Biliary complex 47579 Unlisted laparoscopy procedure, biliary tract
Biliary complex 47711 Excision of bile duct tumour, with or without primary repair of bile duct, extrahepatic
Biliary complex 47712 Excision of bile duct tumour, with or without primary repair of bile duct, intrahepatic
Biliary complex 47715 Excision of bile duct cyst
Biliary complex 47720 Cholecystoenterostomy, direct
Biliary complex 47721 Cholecystoenterostomy, with gastroenterostomy
Biliary complex 47760 Anastomosis, of extrahepatic biliary ducts and gastrointestinal tract
Biliary complex 47765 Anastomosis, of intrahepatic ducts and gastrointestinal tract
Biliary complex 47780 Anastomosis, Roux-en-Y, of extrahepatic biliary ducts and gastrointestinal tract
Biliary complex 47785 Anastomosis, Roux-en-Y, of intrahepatic biliary ducts and gastrointestinal tract
Liver 47120 Hepatectomy, resection of liver, partial lobectomy
Liver 47122 Hepatectomy, resection of liver, trisegmentectomy
Liver 47125 Hepatectomy, resection of liver, total left lobectomy
Liver 47130 Hepatectomy, resection of liver, total right lobectomy
Liver 47379 Unlisted laparoscopic procedure, liver
Liver 47380 Ablation, open, of one or more liver tumour(s), radiofrequency
Pancreas 48120 Excision of lesion of pancreas (e.g. cyst, adenoma)
Pancreas 48140 Pancreatectomy, distal subtotal, with or without splenectomy, without pancreaticojejunostomy
Pancreas 48145 Pancreatectomy, distal subtotal, with or without splenectomy, with pancreaticojejunostomy
Pancreas 48146 Pancreatectomy, distal, near-total with preservation of duodenum (Child-type procedure)
Pancreas 48148 Removal of pancreatic duct
Pancreas 48150 Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy
and gastrojejunostomy, with pancreaticojejunostomy
Pancreas 48152 Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy
and gastrojejunostomy, without pancreaticojejunostomy
Pancreas 48153 Pancreatectomy, proximal subtotal with near-total duodenectomy, choledochoenterostomy and
duodenojejunostomy (pylorus-sparing), with pancreaticojejunostomy
Pancreas 48154 Pancreatectomy, proximal subtotal with near-total duodenectomy, choledochoenterostomy and
duodenojejunostomy (pylorus-sparing), without pancreaticojejunostomy
Pancreas 48155 Pancreatectomy, total
Pancreas 48510 External drainage, pseudocyst of pancreas, open
Pancreas 48520 Internal anastomosis of pancreatic cyst to gastrointestinal tract, direct
Pancreas 48540 Internal anastomosis of pancreatic cyst to gastrointestinal tract, Roux-en-Y
Pancreas 48548 Pancreaticojejunostomy, side-to-side anastomosis (Puestow-type operation)
Pancreas 48999 Unlisted procedure, pancreas
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